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Atopic dermatitis (AD) is the most common atopic disease in young children and most com-mon skin disease in 
childhood. In the Polish population, the incidence of AD in the group of children aged 6–14 is about 4% and it is 
underestimated. The disease is chronic and recurrent, and the leading symptom is skin pruritus that in the mecha-
nism of the vicious circle is accom-panied by scratching that causes generalized infections. The overall problems 
lead to a de-crease in the quality of life of the child and its parents and to an increased risk of psychoso-matic 
diseases. The complex pathomechanism of AD is due to chronic inflammation of the skin, in which various cell 
phenotypes are involved. The management is comprehensive and it is aimed at reducing inflammation, improving 
the skin barrier function, reducing the symptoms of dryness and itching of the skin and secondarily improving 
the quality of life. The treatment includes intensive skincare, anti-inflammatory treatment based on the proactive 
use of topical glucocorticosteroids and topical calcineurin inhibitors. Periods of exacerbation of lesions re-quire 
intensified treatment. In particularly severe, recurrent cases, treatment options can be extended to systemic im-
munosuppressive drugs, with awareness of their adverse effects. Pre-vious year has brought significant progress 
in the current treatment of AD in the form of bio-logical treatment. Cytokines and other mediators that play an 
important role in the pathogene-sis of skin inflammation have become a target for new forms of therapy. Drugs 
for which interleukin (IL)-4 and IL-13 are the targets are particularly represented. Dupilumab is the first biological 
drug approved for the general treatment of children aged >12 years with moderate to severe AD. Another thera-
peutic option for topical use is crisaborole, a phosphodiesterase-4 inhibitor. This study presents the current state 
of research on biological drugs in AD.
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Introduction
Atopic dermatitis (AD) is the most common atopic disease in 
small children and a leading skin disease during childhood. 
AD affects 7–30% children and 1–10% adults depending 
on the type of population or region of the world. Disease 
characteristics are heterogeneous and they vary by region 
and age (1). Large cohort studies indicated that AD occurs in 
11–16% patients in the European population (2). In the Polish 
population, according to the results of ECAP (Epidemiologia 
Chorób Alergicznych w Polsce [Epidemiology of Allergic 
Diseases in Poland]) in the questionnaire survey, where 
in some children the result of the survey was verified by 
54
Journal of Mother and Child
markers, the pathomechanism of inflammation is shown in 
Figure 1 (10).
AD in childhood is very heterogeneous. There is a continuing 
search for predictors defining a phenotype of this disease. 
In one of the large cohort studies, the strongest predictors 
of association with a particular phenotype (cluster) were 
variables such as age of the first symptoms, age at the time 
of diagnosis, number of white blood cells and eosinophils 
and total IgE concentration (11). These parameters allowed 
to identify four phenotypes: A (early beginning of the 
symptoms <2 years old, eosinophilia, increased total IgE 
concentration, allergy to food allergens and high points in 
scoring atopic dermatitis [SCORAD] scale), B (early beginning 
of the symptoms <2 years old, low eosinophilia, low total 
IgE concentration and low IgE specific for food and airborne 
allergens), C (early beginning of the symptoms and increased 
values of CRP and white blood cells) and D (beginning of the 
symptoms >2 years old, increased total IgE concentration and 
high concentration of IgE specific for airborne allergens) (11).
Regardless the attempts to identify phenotypes, the natural 
course of the disease is characterized by a chronic inflammatory 
state with overbearing skin dryness and lichenified lesions, 
periods of flare-ups accompanied by inflammation-related 
parameters such as intense redness, oedema, increased 
inefficiency of the skin barrier, oozing, intense pruritus and 
pain. The chronic phase is associated with predominance of 
lymphocytes Th1, Th17 and their cytokines (interferon and IL-
17A) (12).
In case of flare-up, there is an increased expression of 
lymphocytes Th2, Th22 and their cytokines (IL-4, IL-13 
and IL-22), as well as DCs (12). IL-4 and IL-13 are the key 
cytokines leading to local increase of IgE levels, a part of 
which is characterized by autoreactivity against their own 
the medical examination, the frequency was 3.91, 4.3 and 
3.02%, respectively, in the examined age groups (6–7 years, 
13–14 years and adults), though this frequency seems to be 
underestimated (3).
The disease is chronic and recurrent with the primary 
symptoms resulting from the skin barrier dysfunction 
accompanied by intense itching and characteristics of the 
chronic skin inflammation. The environmental (emotions, 
sweating and physical exercise) and microbiological factors 
(skin colonization with Staphylococcus aureus common in 
these patients) play an important role in the disease flare-
ups, leading to disturbances in sleep and concentration. 
The course of the disease warrants necessity of constant 
employment of time-consuming procedures and treatment 
of recurrent flare-ups. These result in, regardless of patient’s 
age, reduced quality of life, increased risk of psychosomatic 
illnesses such as attention-deficit hyperactivity disorder and 
depression (4). In case of children, the above chronic illness 
leads to reduced quality of life and disturbances in life of the 
entire family (5).
The pathogenesis of AD is complex, and it results from the 
chronic inflammatory status in skin which is associated with 
different phenotypes of lymphocytes (i.e. Th2, Th17, Th22 and 
Th1), other competent immunological cells (innate lymphoid 
cells [ILC] and dendritic cells [DC]) or cells of the skin barrier 
(keratinocytes). The released cytokines, such as IL-4, IL-13, 
IL-17, IL-22, IL-31 and thymic stromal lymphopoietin (TSLP), 
form a network of mutual interactions, sustain chronic 
inflammatory state, weaken barrier function of the skin and 
play a role in disease flares (Table 1) (6, 7). The key role of 
cytokines is associated with Th2 (IL-4, IL-5 and IL-13) (8, 9). 
Taking into account biological markers and current research 
directions on biological treatment in AD targeted at these 
Table 1. Characteristic changes in acute and chronic atopic dermatitis (AD)
Characteristic Exacerbation AD Chronic form AD
Th2 type activation pathway and related cytokines/
chemokines
Increased activity of IL-4, IL-13, IL-31 Increased activity of IL-5, IL-13, IL-31, IL-10, CCL-
5, CCL13, CCL18. Equivocal results for IL-4
Th22 type activation pathway and related cyto-
kines
Increased IL-22 activity Increased activity of IL-22, IL-32
Th1 type activation pathway and related cytokines/
chemokines
A slight increase in IFN-g, MX1, IL-1b, CXCL9-11, 
but not in all phenotypes
Significant increase in IFNg, MX1 (markers associ-
ated with Th-1 cytokine), IL-1b, CXCL9-11
Th17 type activation pathway and related cyto-
kines
A slight increase in the level of IL-17, IL-23p19, 
IL-23p40
The level of activation is similar to that of acute AD
Infiltration of immune cells Infiltration of immune cells Intensification of changes as in the exacerbation
Epidermal changes Increased hyperplasia, epidermal thickening, 
marker proliferation (Ki67, K16, IL-22); reduction in 
the level of epidermal barrier proteins (involucrine, 
loricrin, filaggrin)
Intensification of changes as in the exacerbation
Reduced expression of final protein and lipid dif-
ferentiation
Decreased expression of FLG, LOR, PPL and 
other differentiation proteins; significant lipid 
disorders
Intensification of changes as in the exacerbation
Sources: Moyle et al. (6) and Suárez-Fariñas et al. (7).
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skincare, anti-inflammatory treatment based on topical 
corticosteroids (TCS) with weak to moderate strength of 
action and topical calcineurin inhibitors (TCI). Periods of flare-
ups require intensified treatment, which is mostly based on 
the TCS (13). In some cases, the reason behind unsuccessful 
treatment might be fear of caregivers and/or physicians of 
steroid therapy (14). Systemic corticosteroids (CS) are not 
recommended in AD treatment; however, they are still used in 
the clinical practice despite risks outweighing benefits of such 
treatment (15).
Treatment in some particularly serious, recurrent types of 
disease might also include immunosuppressive systemic 
medications, such as cyclosporine A (CsA), methotrexate 
(MTX) or azathioprine, keeping in mind their associated 
adverse effects. This group of medications is hardly ever 
administered in children. The medications with the well-
documented efficacy and safety include CsA (16) and less 
common MTX (17). The indispensable element of treatment 
includes education of parents/caregivers in prophylaxis of 
exposure to factors worsening skin status, appropriate types 
antigens. Both cytokines play significant role in pruritus. In 
both types of inflammation states, there is a type of ‘vicious 
circle’ where IL-4, IL-13 and IL-22 inhibit the expression of 
filaggrin (FLG), which worsens problems of the skin barrier. 
Keratinocytes release inflammatory mediators, such as 
TSLP, which in turn stimulates Th2 response and promotes 
production of IL-13 and IL-31, and those in conjunction with 
nerve growth factor (NGF), and substance P represents 
strong pruritus mediators. Scratching, secondary to intense 
itchiness, worsens dysfunction of the epidermal barrier, while 
anxiety and psychosomatic discomfort increase experience of 
itchiness that stimulates more scratching (Table 1) (6, 7).
Treatment
Management of AD is complex, and its main goal is to 
decrease inflammatory status, improve skin barrier function 
and decrease skin dryness and pruritus resulting in 
improvement of quality of life. Treatment includes intensive 
Figure 1. The pathomechanism of inflammation and current research directions for biological treatment of AD (courtesy of HL Nguyen, MM 
Tollefson, with permission from the Springer Nature publishing house) [10]
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pathogenesis of the skin inflammatory status. There is a 
special group of medications that target IL-13. However, 
some of them, despite their potentially beneficial effect in 
regard to their pathophysiology/type of mechanism, did not 
show expected results in the treatment of AD in children, i.e. 
medications blocking interleukins (ILs), such as IL-5 and IL-
22, and prostaglandin D
2 receptor 2 (CRTh2) (6, 7, 12, 19).
IL-4/IL-13 inhibitors
Potential efficacy of monoclonal antibodies specific for IL-
13 results from its principal role in development of the 
inflammation. In skin biopsy in children with AD, there was 
increased expression of IL-13 mRNA compared with the skin 
of healthy children, and the level of IL-13 mRNA expression 
was proportional to the severity of the disease. Moreover, 
overexpression of IL-13 is the cause of the decreased 
epidermal integrity by deregulation of the key components of 
the skin components. Treatment with systemic medications 
such as CsA might lead to decrease in IL-13 level, and the 
current results of the studies on dupilumab, an antibody 
specific for IL-13/IL-14, confirm key role of IL-13 in the 
development of inflammation. Therefore, the targeted 
treatment aimed against the most central point in AD 
pathology might maximize effectiveness of the treatment 
and may limit its toxicity (20).
skincare and external type of management (Table 2) (18, 19). 
Aside from introduction of TCI, there was no breakthrough in 
treatment of AD since many years.
New age in therapy, biological treatment, personal-
ized therapy
The medications targeted against mediators of inflammation, 
such as cytokines (mostly Th2 profiles such as IL-4, IL-13, 
TSLP, IL-25, IL-31 and IL-33), enzymes (Janus kinase and 
phospholipase A2), receptors (receptors specific for aryl 
carbohydrates) and skin microbiota, are the targets for the 
potential new therapies in the treatment of AD. The recent 
years brought considerable progress in the existing treatment 
options, opening up possibilities to treat serious, recurrent 
types of disease based on the biological agents (10). Even 
though the majority of those medications is addressed to the 
patients regardless of their AD phenotype, it is possible that as 
in asthma, biological treatment might become personalized, 
targeted against specific markers and adjusted to particular 
phenotypes (pattern of symptoms), endotypes (pattern of 
markers specific for particular pathology) or teratypes (pattern 
of response to specific treatment) of the disease.
Currently, as part of personalized treatment, there are 
attempts to propose new treatments that target cytokines 
and other mediators are playing significant role in the 
Table 2. Strategy for gradual treatment of atopic dermatitis (AD)
Chronic treatment Treatment of exacerbations (often recommended in a hospital setting)
Severity III
SCORAD ³ 50 
•  1st line: dupilumab, cyclosporin A, phototherapy (in 
selected cases)
•  2nd line: methotrexate, azathioprine
•  Periodic intensification of basic treatment such as 
emollient for the skin under a wet dressing
•  Intensification of basic treatment such as emollient for the skin under a 
moist dressing
•  Systemic glucocorticosteroid (GCS) (short – maximum up to 14 days) and/or 
local GCS daily all over the skin (possibly for several under the dressing)
•  Limitation of pyodermisation
Antibiotic in general (first generation cephalosporins or clindamycin preferred)
•  Antibiotic topically (fusidic acid, mupirocin, retapamulin)
•  Mupirocin locally on the skin of the atrium of the nose in attempts to eradi-
cate the carrier of S. aureus
•  Disinfectants (polidocanol, octenidine, chlorhexidine, triclosan, KMnO4) and 
desiccants (tannin preparations)
•  Herpes infection
•  Acyclovir and observation in a hospital setting
•  Yeast or dermatophyte infection
•  Consider systemic treatment with imidazole derivatives (fluconazole >1 year 
old, itraconazole >12 years old), miconazole, terbinafine
•  Molluscum contagiosum infection – usually self-limiting
•  Technological fabrics with silver ions in some patients
Severity II
SCORAD ³ 25–49
•  Local GCS with weak to moderate proactive 
strength
•  Proactive calcineurin (Protopic, Elidel) or PhD4 
(Eucrisa) topical inhibitors
•  Periodic intensification of basic treatment such as 
emollient for the skin under a wet dressing
Severity I
SCORAD < 25 
•  Local GCS with weak proactive strength
•  Topical calcineurin inhibitors (Elidel) proactively or 
PhD4 (Eucrisa)
Basic treatment for 
all levels of severity 
AD
•  Avoiding irritants (e.g. rough fabrics) and aggravating (sweating, overheating, stress)
•  Dermocosmetics for washing the skin
•  Emollients ³ 2 times per day used generously (after washing according to the principle of up to 5 min)
•  Elimination diet in justified cases
•  Probiotics with documented effects
•  Symptomatic antipruritic drugs
Sources: Klasa and Cichocka-Jarosz (18), own modification based on Brunner et al. (19).
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limiting toxicity. The adverse effects encountered during 
treatment, such as conjunctivitis, eyelid inflammation, oral 
herpes, eosinophilia, rhinitis, pharyngitis, headaches and 
upper respiratory tract infections, were very few and almost 
negligible (21). Dupilumab is manufactured in two doses at 
200 and 300 mg for subcutaneous route. Initially drug was 
registered by Food and Drug Administration (FDA) in the USA 
for adults (29 March 2017) and subsequently for adolescents 
(11 March 2019), followed by European Medicines Agency 
(EMA) approval in the European Union (EU) (6 August 2019). 
As of 26 September 2017, Dupixent at the dose 300 mg 
(pre-filled syringe 150 mg/ml and auto-injector 150 mg/ml) is 
registered in Poland for use in the treatment of moderate to 
severe AD in adults and currently also in adolescents aged 
12 years and older who are eligible for general treatment.
Up-dosing schedule includes as follows: in adults, initiating 
dose equals 600 mg (separated into two injections), followed 
by 300 mg every 2 weeks; in teenagers over 12 years, the dose 
depends on body weight – in those of body weight <60 kg the 
initial dose equals 400 mg (two injections of 200 mg), followed 
by 200 mg fortnightly, and in those of body weight >60 kg the 
schedule is the same as in adult patients (24, 25).
Tralokinumab
Tralokinumab is a monoclonal antibody that strongly blocks 
association of IL-13 with the receptors specific for IL-
13Ra1 and IL-13Ra2 and disrupts signal transduction to the 
receptors IL-4Ra/IL-13Ra1. The goal of the clinical studies 
was the analysis of efficiency and safety of tralokinumab 
in monotherapy (ClinicalTrials.gov: NCT03131648, 
NCT03160885) or in combination with TCS (ClinicalTrials.
gov NCT03363854, NCT03761537) in adults with moderate 
to serious AD. In phase II study there were 204 participants, 
randomized into four arms 1:1:1:1 who received tralokinumab 
at the doses 45, 150 and 300 mg or placebo, respectively, 
every 2 weeks for 12 months. Along with that treatment, 
concurrent application of the TCS was served. The final results 
showed that 300 mg of tralokinumab resulted in a significant 
reduction of AD symptoms compared with the placebo group, 
evaluated by means of both EASI and SCORAD scores 
(ClinicalTrials.gov: NCT02347176) (26). At the next stage, the 
clinical study evaluating monotherapy with tralokinumab for 
adolescent subjects with moderate to severe AD was initiated 
(ClinicalTrials.gov: NCT03526861, NCT03562377).
Lebrikizumab
Lebrikizumab is a humanized monoclonal antibody with a high 
affinity for IL-13. The results of the studies so far verified that 
lebrikizumab at a dose of 125 mg applied subcutaneously every 
4 weeks, combined with application of TCS, led to reduced need 
for immunosuppressive drugs in the patients with AD. In phase 
II study, lebrikizumab used as an additional therapy to the TCS 
Dupilumab
Treatment options in patients diagnosed with moderate or 
severe AD used to be limited. The first biological medication, 
approved for treatment of adults and children over 12 years, 
diagnosed with moderate and serious type of AD is dupilumab 
(Dupixent®, Sanofi-Aventis Groupe, Paris). It is a monoclonal 
antibody blocking subunit alpha, a common one for the 
receptors of IL-14 (IL-4Ra) and IL-13 (21). Cytokines such as 
IL-4 and IL-13 exert a direct key influence on the epidermis of 
the patients with AD by (1) blocking terminal differentiation with 
potential hyperplasia of the regulatory loop (hyperprolifieration 
of keratinocytes), (2) stimulation of remodelling of the skin 
towards sponge layer, (3) inhibition of lipid synthesis in the 
skin, (4) reduced synthesis of antimicrobial peptides (22) and 
(5) facilitation of the skin colonization by S. aureus (23).
The results in the key phase 3 of the (clinical) study to 
determine the effectiveness of dupilumab in monotherapy in 
patients over 12 years with uncontrolled AD (ClinicalTrials.gov: 
NCT03345914) were comparable with the adult population 
(ClinicalTrials.gov: NCT02277769, NCT02277743):
• In the Eczema Area and Severity Index (EASI) scale, 
there was a triple improvement in comparison with the 
placebo group, 66% vs 24%, respectively.
• There were above 10 times more treated patients who 
achieved a complete remission of the skin changes 
compared with the placebo group, 24% vs 2%, respectively.
• In the EASI-75, there were five times more patients 
who noticed improvement of their skin state by at least 
75% compared with the placebo group, 42% vs 5%, 
respectively.
• There were above seven times more patients who 
reported decreased pruritus compared with the placebo 
group, 37% vs 5%, respectively.
• There was a significant decrease in the serum 
inflammatory biomarkers, including those specific for IgE 
allergens in the patients treated with dupilumab.
According to EMA Pediatric Committee decision (Opinion 
of the Paediatric Committee on the acceptance on the 
modification of an agreed Paediatric Investigation Plan, EMA/
PDCO/92908/2018), there is an agreement for conducting the 
clinical trials dedicated to the evaluation of safety and efficacy 
of dupilumab in patients aged over 6 months till 18 years 
(24). Currently in children aged between 6 and 12 years, and 
6 months and 6 years, with AD, phase II–IV clinical studies were 
initiated (ClinicalTrials.gov: NCT02407756, NCT02612454, 
NCT03411837, NCT03428646, NCT03549416). Finally in 
pre-registration data, dupilumab was evaluated in >30 clinical 
studies in >7,000 patients aged over 12 years. Safety profile 
of dupilumab used in children over 12 years for 52 weeks was 
appraised similarly to the studies in adult populations (25). So 
far, all the results of the studies on dupilumab demonstrated 
high safety profile, good drug tolerability and lack of dose-
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skin inflammation and sleep disturbances compared with 
placebo control. However, the results in EASI, SCORAD 
and body surface area (BSA) scales were not significantly 
different between the study and control groups after 12 weeks 
of treatment. Increasing duration of the treatment with 
nemolizumab up to 64 weeks resulted in decreased skin 
itching; however, the results were not compared with the control 
group and therefore the results could not be verified. The most 
common acute adverse effects of the treatment observed 
in >2% of the patients randomized to receive nemolizumab 
included worsening of AD (8%), upper respiratory infection 
(4%), rhinitis with pharyngitis (4%), peripheral oedema (3%), 
increased activity of creatine kinase (3%) and local reactions 
at the site of injection (2%). Currently, there are phase I–III 
studies in the patients older than 6 years (ClinicalTrials.gov: 
JapicCTI-173740, JapicCTI-183894, NCT03100344).
The primary outcome of the nemolizumab study was reduction 
in skin itching intensity following 12 weeks of treatment as 
determined by the visual analogue scale (VAS). The secondary 
outcome was the level of skin itching intensity as determined 
by VAS and SCORAD scale (30). There were 264 patients 
enrolled in part A, out of them 216 completed the study. 
There were 191 patients enrolled in part B, out of them 131 
completed the study. The patients enrolled in part A suffered 
from more intense pruritus according to VAS, and moderate to 
serious AD according to IGA, BSA and EASI scales. The most 
common allergic illness in those patients was allergic rhinitis 
(n = 91), followed by asthma (n = 34) patients. The most 
spectacular improvement was observed in the group, which 
received nemolizumab at 0.5 mg/kg. The first results were 
observed during 16th week of treatment that corresponded to 
4th week of treatment with the active ingredient in the patients 
who received placebo for 12 weeks during part A followed by 
nemolizumab. There were no safety-related adverse effects 
associated with long-term nemolizumab use (30).
Inhibitors of IL-12 and IL-23
Ustekinumab
Ustekinumab is a human monoclonal antibody specific for 
IL-12 and IL-23. IL-23 is indispensable for the generation of 
Th-17 cytokine, which plays a key role in the pathogenesis 
of inflammation. In a mouse model, it was demonstrated that 
IL-23 mediated inflammation typical for AD, and IL-23 level 
was proportional to degree of severity of the AD symptoms. 
The results of ustekinumab usefulness in the treatment of 
AD are barely convincing (ClinicalTrials.gov: NCT01806662, 
NCT01945086). In some cases, ustekinumab seemed to be 
beneficial; however, the treatment results were either very 
weak or absent in the remaining cases (31).
in adults showed better results compared with the patients 
receiving placebo and TCS (ClinicalTrials.gov: NCT02465606, 
NCT04178967, NCT04146363) (20). The next step is the 
ongoing study assessing the safety and efficacy of lebrikizumab 
in adolescent patients with moderate to severe AD (ADore) 
(ClinicalTrials.gov: NCT04250350, NCT04250337).
Pitrakinra
Pitrakinra is a human recombinant variant (mutein) of 
IL-4 which binds subunit alpha of IL-4 and blocks activity 
of IL-4 and IL-3; therefore, it prevents development of 
inflammation induced by those cytokines. Animal models of 
asthma and AD show that pitrakinra exerts strong blocking 
effect on proliferation mediated by IL-4 and IL-13, and it 
reduces allergens-induced inflammation. In phase I and II 
studies in patients with asthma, pitrakinra administered by 
either subcutaneous injection or by inhalation decreased 
inflammation in the respiratory tract.
In 2007, the drug was approved to treat patients with asthma 
(27). Phase IIa of the clinical study to verify efficacy of 
pitrakinra (Aeroderm) compared with placebo in the patients 
with moderate and serious type of AD was completed 
(ClinicalTrials.gov: NCT00676884). Pitrakinra administered 
subcutaneously showed some promising results in the 
treatment of AD; however, the results are not yet published. 
Further research is required to accurately determine the 
value, characteristics, effectiveness and its safety.
Inhibitors of IL-31/IL-31Ra
IL-31 is a cytokine released by macrophages, dendritic 
cells, eosinophils, basophils, mastocytes, keratinocytes and 
Th2 cells. Association of IL-31 with its receptor alpha (IL-
31Ra) on the immunological cells, keratinocytes and neural 
fibres results in the activation of Janus kinase and Signal 
Transducer and Activator of Transcription (JAK/STAT), which 
plays important role in the development of pruritus (28). 
Prevention of IL-31 binding to IL-31Ra might significantly 
reduce itching in patients with AD.
Nemolizumab
Nemolizumab (CIM3312) is a monoclonal antibody specific for 
IL-31 receptor, hence it blocks signal transmission mediated 
by IL-31. IL-31 is a key cytokine that regulates pruritus, which 
worsens epithelial dysfunction leading to easier access of 
allergens (29). Until present, there are two clinical studies 
to determine efficacy and safety of nemolizumab. Phase I 
study showed significant decrease in pruritus according to 
EASI scale. In phase II study, safety and tolerability of the 
medicine were tested. The studies showed that nemolizumab 
was well tolerated, and it decreased intensity of the pruritus, 
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Abrocitinib
Abrocitinib (Pf-04965842) is an oral JAK1 inhibitor which 
is characterized by very few side effects, out of which 
the most common ones include upper respiratory tract 
infections and AD flare-ups. Phase II studies in adults verified 
efficacy and good tolerance of the drug in the patients with 
moderate and serious AD (34). Currently, phase III study is 
to determine the efficacy of the Pf-04965842 in youth over 
12 years (ClinicalTrials.gov: NCT03575871, NCT03349060, 
NCT03422822, NCT03627767).
Ruxolitinib
Ruxolitinib is a locally acting JAK1/JAK2 inhibitor, initially 
used in myelofibrosis and polycythemia vera. Currently, it is 
tested in adults and children over 12 years with AD. Phase IIB 
studies in adults initially fulfilled all the primary and secondary 
aims (35). Currently, phase I study is carried out in children 
aged 12–17 years (ClinicalTrials.gov: NCT03257644).
ASN002
ASN002 is an oral inhibitor of JAK, tyrosine kinase 2 (TYK2) 
and spleen tyrosine kinase (SYK). Inhibition of SYK disrupts 
the function of B cells, mastocytes, macrophages, IL-17, Th1, 
Th2 and Th17, and simultaneously it regulates differentiation 
of keratinocytes. All the adult patients included in this study 
reached EASI-50 after 4 weeks of treatment (ClinicalTrials.
gov: NCT03139981) (36).
Delgocitinib
Deglocitinib is a local inhibitor of JAK/TYK2 currently 
tested in children aged 12–17 years, adults with AD and 
adults with hand eczema (ClinicalTrials.gov: NCT0372572, 
NCT03826901, NCT03683719). The observed side effects 
included pharyngitis, lymphopaenia and erysipelas (37).
Mild and moderate AD
Topical inhibitors of phosphodiesterase-4
In patients with AD, there is an elevated level of 
phosphodiesterase-4 (PDE-4) in the lymphocytes. PDE-4 
is an intracellular enzyme associated with synthesis of pro-
inflammatory cytokines, which plays a role in inflammatory 
pathways. Its inhibition blocks inflammatory cytokines and 
inflammation development in the skin. PDE-4 inhibition 
became a chance for new type of local treatment (38).
One of the issues regarding current local treatment of AD 
is associated with safety of its long-term use. Until recently, 
the approved methods of local treatment included TCS 
and TCI. However, despite acceptable treatment results, 
the recommendations do not advice prolonged use of high 
Inhibitors of JAK-STAT
JAK-STAT is a pathway for signal transduction from the 
cellular membrane to the nucleus. It regulates immunological 
system by pro-inflammatory cytokines, such as IL-4, IL-5, 
IL-13, IL-31 and TSLP. Association of the ligands with their 
receptors in the cell membrane leads to JAK-STAT activation; 
therefore, inhibition of this complex blocks the development 
of inflammation (10). JAK inhibitors administered orally or 
locally appear to provide a promising therapeutic option for 
adults and children with AD, demonstrating high efficacy in 
comparison with placebo controls. In addition, they result 
in significant reduction in skin itching. Those drugs are well 
tolerated with very few side effects (10).
Baricitinib
Baricitinib is an oral JAK1/JAK2 inhibitor which was tested 
only in the adult population so far. There were 124 patients in 
phase II clinical study. There were significantly more patients 
who achieved improvement by >50% compared with the initial 
skin condition according to EASI-50 scale in the treated group 
in comparison with placebo, 61% vs 37%, p = 0.027 (32). 
All the patients included in this study used TCS for a month 
preceding baricitinib, hence its efficacy in monotherapy was 
unknown. The recorded side effects included lymphopenia, 
neutropenia, worsening of AD, headaches, without any other 
serious symptoms. Currently, there are phase III studies 
in adults to determine safety and efficacy of baricitinib, 
along with its efficacy in monotherapy (ClinicalTrials.
gov: NCT03334396, NCT03334435, NCT03435081, 
NCT03559270, NCT03334422, NCT03428100).
Upadacitinib
Upadacitinib is an oral JAK1 inhibitor tested in children 
aged 2–17 years and in adults with AD. Phase IIB studies in 
adults showed better efficacy of upadacitinib compared with 
placebo (p < 0.001) (31). The most common side effects 
were upper respiratory tract infections (33). Currently, efficacy 
of upadacitinib is analysed in phase III study in youths and 
adults (ClinicalTrials.gov: NCT03569293, NCT03568318, 
NCT03607422, NCT03661138), while phase I study was just 
launched in children aged 2–12 years (ClinicalTrials.gov: 
NCT03646604). Guttman-Yassky et al. presented results of 
phase II study in adults with AD which evaluated upadacitinib 
efficacy by serum IgE levels and eosinophilia (33). During 
the study, the patients received upadacitinib 7.5, 15 and 
30 mg or placebo daily. According to EASI scale, the average 
percentage of improvement from the initial condition to 16th 
week of treatment was significantly higher in all the patients 
treated with upadacitinib regardless of their dose compared 
with placebo.
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studies on age group 3 months to 2 years are also available 
(NCT03356977). First, crisaborole (Eucrisa, Pfizer Labs, NY) 
was approved by FDA in the USA (14 December 2016) for 
children aged >2 years with mild to moderate AD, but currently 
in the USA it is registered for children older than 3 months. On 
30 January 2020, crisaborole (Staquis, Pfizer Europe MA EEIG) 
as 20 mg/g ointment was approved by EMA for use in the EU in 
adults and children aged >2 years.
RVT-501
RVT-501 is a local PDE-4 inhibitor which was tested in 
adults and children aged 2–15 years. Phase I and II studies 
of 0.2% RVT-501 used for 12 weeks showed improvement 
according to EASI and SCORAD scores. The side effects 
included gout, enterocolitis and erythema (39). Phase II study 
with higher, 0.5% concentration of RVT-501 was completed; 
however, the results are not published yet (ClinicalTrials.gov: 
NCT03394677, NCT02950922).
Biological drugs studied in AD and their targets are 
summarized in Table 3 (11). The list of clinical trials conducted 
for biological drugs in AD is presented in Table 4 (40).
concentrations of TCS because they might lead to serious 
adverse effects, such as local skin atrophy and teleangiectasia, 
or systemic outcomes due to dermal drug absorption, such 
as inhibition of hypothalamus–pituitary axis. Since AD is 
a chronic and relapsing disease, it requires continuous 
treatment with the least number of possible adverse effects. 
There was no new treatment option approved for the local 
use in the past 15 years.
Crisaborole
Crisaborole is a non-steroid, anti-inflammatory inhibitor of 
PDE-4. The drug as 2% ointment blocks PDE-4-dependent 
degradation of adenosine cyclic monophosphate. The results 
of the preclinical studies verified effective penetration of 
crisaborole through the skin. In addition, the drug is quickly 
metabolized to inactive metabolites, which determines the safety 
of its use. Phase III study demonstrated very few side effects 
of crisaborole ointment use (ClinicalTrials.gov: NCT04040192, 
NCT02118766). It appears to be the next therapeutic option in 
prolonged local treatment of AD, with the treatment potential 
comparable with pimecrolimus (38). Currently, data from 
Table 3. Treatment depending on the severity of atopic dermatitis (AD)
Medication Mechanism of action Characteristics
AD: mild and moderate form
PDE-4 inhibitors
Crisaborole Inhibits the degradation of PDE4-dependent cyclic adenosine 
monophosphate, which in turn regulates T-cell signalling 
pathways, enhancing cellular control of inflammation. Topical 
drug – 2% ointment
Phase IV studies in children between 3 and 24 months of age 
have been completed
RVT-501 Phosphodiesterase 4 Inhibitors (PDE4i). Topical drug – 0.5% 
ointment
Phase II studies in children aged between 2 and 17 years have 
been completed.
Inhibitors JAK-STAT
Tofacitinib Blocking the cell signal transduction pathway inhibits pro-
inflammatory cytokines
In the treatment of AD, it has so far only been tested in adults
AD: moderate and severe form
Inhibitors JAK-STAT
Baricitinib Inhibitor JAK1/JAK2 – oral drug All patients included in this study used local GCS 1 month before 
starting baricitinib therapy, therefore the efficacy of baricitinib 
monotherapy is unknown
Upadacitinib Inhibitor JAK1 – oral drug Currently in the research phase in children aged from 2 to 
17 years and adults with AD.
Abrocitinib (Pf-
04965842)
Inhibitor JAK1 – oral drug Currently in phase III studies assessing the effectiveness of the 
drug in adolescents aged >12 years
Ruxolitinib Inhibitor JAK1/JAK2 – topical drug Initially used to treat myelofibrosis and true polycythaemia, it is 
currently studied in children aged between 12 and 17 years and 
adults with AD
ASN002 Inhibitor JAK/TYK2/SYK – oral drug Phase IIa studies in adults aged between 18 and 75 years have 
been completed.
Delegocitinib Inhibitor JAK/TYK2 – topical drug Examined in children aged from 12 to 17 years and adults with AD.
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Phosphodiesterase 4 Inhibitors (PDE4i)
Roflumilast Inhibitor PDE4 – topical drug Until present, tested only in adults – phase IIa studies showed no 
improvement after using 0.5% cream Roflumilast
Apremilast Inhibitor PDE4 – oral drug Positive results in the treatment of children and adults with 
refractory AD. High frequency of undesirable activities in the form 
of cellulitis. No further studies are planned due to the risk and 
benefit analysis
CRTH2 receptor antagonists
Fevipiprant/Timapiprant The antagonism on the CRTH2 receptor suppresses the 
formation of the inflammatory process
Clinical studies have not demonstrated efficacy of the drug rela-
tive to placebo (NCT01785602, NCT02002208)
Thymus stromal lymphopoietin (TSLP) and OX40 inhibitors
GBR-830 Inhibitor TSLP (TSLP induces immune cells to produce pro-
inflammatory cytokines). Anti-OX40 monoclonal antibody
Phase II is completed in adults
Tezepelumab Inhibitor TSLP. Anti-TSLP monoclonal antibody To date, studies only in adults – phase IIa studies lack satisfactory 
results
(TAMA) therapeutic aryl hydrocarbon receptor modulating agent (AhR)
Tapinarof TAMA Tested in children aged 12–17 years and adults. Phase III re-
search scheduled for 2019
Inhibitors IL-4/IL-13
Dupilumab Human monoclonal antibody blocking a subunit, common to 
IL-4 (IL-4Ra) and IL-13 receptors
To date, dupilumab (Dupixent) has been studied in >7,000 
patients aged >12 years, in >30 clinical trials giving very good 
treatment results (description in the text)
Pitrakinra IL-4 mutein – binds the IL-4Ra receptor by inhibiting the 
production of IL-4 and IL-13
Phase II clinical trials in adults have been completed
Tralokinumab/Lebriki-
zumab
Anti-IL-13 monoclonal antibody Lebrikizumab and tralokinumab are undergoing phase III studies
Inhibitors IL-5
Mepolizumab Anti-IL-5 monoclonal antibody inhibits eosinophil activity Two clinical trials in adults with AD have been unsuccessful
Inhibitors IL-22
Fezakinumab Anti-IL-22 monoclonal antibody Phase IIa studies have shown that this medicine has little poten-
tial to treat AD
Inhibitors IL-12/IL-23
Ustekinumab 
Anti-IL-12/IL-23 monoclonal antibody The results of phase IIa studies are not convincing
Inhibitors IL-31/IL-31Ra
Nemolizumab IL-31Ra monoclonal antibody Phase I studies showed a significant reduction of pruritus and 
phase II studies evaluated the safety and tolerability of the drug. 
These studies showed that treatment with nemolizumab is well 
tolerated and it reduces the severity of pruritus, dermatitis and 
sleep disorders compared with placebo
BMS-981164 Monoclonal antibody IL-31 Phase I studies in 2015 – no results have been published so far
Neurokinin-1 Receptor Antagonists (NK1RA)
Serlopitant NK1R antagonist – oral drug Effective in the treatment of chronic pruritus in adults; however, 
phase II drug research in patients with AD did not bring satisfac-
tory results
Tradipitant NK1R antagonist – oral drug Phase III drug research is currently underway
K-Opioid Receptor Agonists (KOR)
Asimadoline Agonist KOR – oral drug Phase II drug studies have been completed. Effective in reducing 
itching at night
Histamin Receptor Antagonists-4 (H4R)
ZPL-389 Antagonist H4R Studies in adults only. The advantage over placebo has not been 
demonstrated. Phase IIB study is currently underway
Immunoglobulin E (IgE) inhibitors
Omalizumab Anti-IgE monoclonal antibody There are no satisfactory treatment effects in patients with AD. A 
drug used to treat asthma
Ligelizumab Anti-IgE monoclonal antibody Higher affinity for IgE than omalizumab. Phase II RCT completed
Source: Seo et al. (11).
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Table 4. List of clinical trials conducted for biological drugs in atopic dermatitis (AD)
Medication Target Study phase Manufacturer www.ClinicalTrials.gov Target endotype AD phenotype
Dupilumab
Dupixent 
IL-4Ra Approved by FDA 2017 
– adults,






Phase III in progress – patients 
>18 years old
NCT02407756
Phase II completed – in children 
12–18 years old, moderate and 
severe AD
NCT02612454
Phase III in progress – in children 
³6 months–18 years old
NCT03054428




Patients ³6 to <18 years old
NCT02612454
Phase III




Patients ³12 years old
NCT03428646
Observation of patients receiving 
Dupixent
Patients ³12 years old
NCT03549416
New systemic treatment options 
in patients with AD, including 
dupilumab (conjunctivitis during 
dupilumab treatment)
Patients: children, adults
Th2/Tc2 All AD phenotypes
Pitakinra/Aeroderm IL-4 Phase II completed Aerovance, 
Berkeley, CA
NCT00676884
Patients >18 years old
Th2/Tc2 All AD phenotypes




Patients >18 years old
Th2/Tc2 AD with elevated 
eosinophils
Tralokinumab IL-13 Phase II completed MedImmune, 
Gaithersburg, MD
NCT02347176
Patients >18 years old
Th2/Tc2 All AD phenotypes








Patients >18 years old
NCT04250337, NCT04250350
Patients 12-17 years old
active
Th2/Tc2 All AD phenotypes
QAW039/Fevipip-
rant






Patients >18 years old
Th2/Tc2 All AD phenotypes






Patients >18 years old
Th2/Tc2 All AD phenotypes
AMG157/tezepe-
lumab
TSLP Phase I completed Amgen, Newbury 
Park, CA
NCT00757042
Patients >18 years old
Th2/Tc2, Th17 All AD phenotypes, 
prevention of al-
lergic march
MK-8226 TSLPR Phase I completed Merck, White-
house Station, NJ
NCT01732510
Patients >18 years old
Th2/Tc2, Th17 All AD phenotypes, 
prevention of al-
lergic march
GBR830 OX40 Phase I completed Glenmark, Mum-
bai, India
NCT02683928
Patients >18 years old
Th2/Tc2 All AD phenotypes




Patients >18 years old
Th2/Tc2 All AD phenotypes
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Medication Target Study phase Manufacturer www.ClinicalTrials.gov Target endotype AD phenotype
QGE031 IgE Phase II completed Novartis NCT01552629
Patients >18 years old
Allergic sensitization Extrinsic AD, AD in 
African Americans, 
AD in Asians, child-
hood AD




Patients >18 years old
Th1, Th2, Th22, 






JAK1/2 Phase II completed Eli Lilly, India-
napolis, IN
NCT02576938
Patients >18 years old
Th1, Th2, Th22, 






JAK1 Phase II completed AbbVie, Lake 
Bluff, IL
NCT02925117
Patients >18 years old
Th1, Th2, Th22, 








Patients >18 years old
Th1, Th2, Th22, 





PF-04965842 JAK1 Phase III completed Pfizer, New York, 
NY
NCT03349060
Patients >12 years old
Th1, Th2, Th22, 






PDE4 Approved by FDA 2016 
>2 years
FDA 2020 >3 months











Roflumilast PDE4 Phase II completed AstraZeneca, 
Cambridge, UK
NCT01856764
























IL-12/23p40 Phase II completed Janssen, Beerse, 
Belgium
NCT01806662
Patients >18 years old
Th17, Th1, Th22 Intrinsic AD, AD in 
Asians, childhood 




IL-31R Phase II completed Chugai, Tokyo, 
Japan
NCT01986933
Patients >18 years old
Pruritus/Th2 All AD phenotypes




Patients >18 years old
Pruritus/Th2 All AD phenotypes
ILV-094/Feza-
kinumab
IL-22 Phase II completed Pfizer NCT01941537
Patients >18 years old
Th22, Th17 Intrinsic AD, AD in 
Asians, adult EA 




IL-17A Phase II completed Novartis NCT02594098
Patients >18 years old
Th17 (and IL-22) Intrinsic AD, AD in 
Asians, children 
and young adults 
from AD





Patients >18 years old Th17
Intrinsic AD, AD in 
Asians, children 
and young adults 
from AD
Source: Czarnowicki et al. (40).
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biologics and emerging therapeutic approaches. Exp Dermatol. 
2019;28(7):756–68. doi: 10.1111/exd.13911
7. Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de 
Guzman Strong C, et al. Intrinsic atopic dermatitis shows similar 
TH2 and higher TH17 immune activation compared with extrinsic 
atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–70. 
doi: 10.1016/j.jaci.2013.04.046
8. Osinka K, Dumycz K, Kwiek B, Feleszko W. Novel therapeutic ap-
proaches to atopic dermatitis. Arch Immunol Ther Exp (Warsz). 
2018;66(3):171–81. doi: 10.1007/s00005-017-0487-1
9. Brunner PM, Israel A, Zhang N, Leonard A, Wen HC, Huynh T, 
et al. Early-onset pediatric atopic dermatitis is characterized 
by TH2/TH17/TH22-centered inflammation and lipid alterations. J 
Allergy Clin Immunol. 2018;141(6):2094–106. doi: 10.1016/j.
jaci.2018.02.040
10. Nguyen HL, Anderson KR, Tollefson MM. New and emerg-
ing therapies for pediatric atopic dermatitis. Paediatr Drugs. 
2019;21(4):239–60. doi: 10.1007/s40272-019-00342-w
11. Seo E, Yoon J, Jung S, Lee J, Lee BH, Yu J. Phenotypes of atopic 
dermatitis identified by cluster analysis in early childhood. J Der-
matol. 2019;46(2):117–23. doi: 10.1111/1346-8138.14714
12. Eyerich K, Novak N. Immunology of atopic eczema: overcoming 
the Th1/Th2 paradigm. Allergy. 2013;68(8):974–82. doi: 10.1111/
all.12184
13. Glines KR, Stiff KM, Freeze M, Cline A, Stowd LC, Feldman 
SR. An update on the topical and oral therapy options for treat-
ing pediatric atopic dermatitis. Expert Opin Pharmacother. 
2019;20(5):621–29. doi: 1.1080/14656566.2018.1561868
14. Bos B, Antonescu I, Osinga H, Veenje S, de Jong K, de Vries 
TW. Corticosteroid phobia (corticophobia) in parents of young 
children with atopic dermatitis and their health care providers. 
Pediatr Dermatol. 2019;36(1):100–4. doi: 10.1111/pde.13698
15. Alexander T, Maxim E, Cardwell LA, Chawla A, Feldman SR. 
Prescriptions for atopic dermatitis: oral corticosteroids remain 
commonplace. J Dermatolog Treat. 2018;29(3):238–40. doi: 
10.1080/09546634.2017.1365112
16. Sarıcaoğlu H, Yazici S, Zorlu Ö, Bülbül Başkan E, Aydoğan K. 
Cyclosporine-A for severe childhood atopic dermatitis: clini-
cal experience on efficacy and safety profile. Turk J Med Sci. 
2018;48(5):933–8. doi: 10.3906/sag-1711-7
17. Taieb Y, Baum S, Ben Amitai D, Barzilai A, Greenberger S. The use 
of methotrexate for treating childhood atopic dermatitis: A multi-
center retrospective study. J Dermatolog Treat. 2019;30(3):240–
4. doi: 10.1080/09546634.2018.1508816
18. Klasa B, Cichocka-Jarosz E. Aktualne możliwości leczenia 
atopowego zapalenia skóry z perspektywy pediatry. The current 
possibilities of treatment for atopic dermatitis from pediatrician’s 
perspective. Przegląd Lekarski. 2017;74(8):399–404.
19. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of 
atopic dermatitis and its reversibility with broad-spectrum and tar-
geted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–76. 
doi: 10.1016/j.jaci.2017.01.011
Summary
Approval of dupilumab for the treatment of patients with 
AD was a breakthrough in modern approach to the patients 
suffering from AD. Discovery of IL-4 and IL-13 role (in 
inflammation process) allowed to create a biological drug, 
which inhibited the above cytokines leading to significant 
decrease of AD symptoms while maintaining a good safety 
profile. Opening the way for research into biological drugs 
creates hope for the future for more personalized (targeted on 
phenotype, biomarkers and individual response to treatment) 
therapy of patients with AD. The next step for Polish patients 
with AD will be the possibility of gaining access to treatment 
due to the drug programme on dupilumab.
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